Posts tagged COVID-19
Phase 3 Clinical Trial Demonstrates Combined Metabolic Activators (CMAs) Accelerates Recovery in Mild-to-Moderate COVID-19
Phase 3 Clinical Trial Demonstrates Combined Metabolic Activators (CMAs) Accelerates Recovery in Mild-to-Moderate COVID-19

Results of a phase 3, double-blind, placebo-controlled trial assessing whether a mixture of Combined Metabolic Activators (CMAs) targeted at mitochondrial function, could improve metabolic function and aid the recovery of mild-to-moderate COVID-19 infected individuals, are now available in the peer-reviewed journal Advanced Science.

The study, conducted at Umraniye Teaching and Research Hospital, University of Health Sciences, Istanbul, Turkey, found that the CMAs, which included nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate, when delivered in combination with standard of care, experienced a statistically significant, 3.5 day reduction in recovery time in the COVID-19 infected patients.[1]

Read More
Expert AnalysisANAD StaffCOVID-19, Clinical Studies
New Phase 2 Clinical in COVID-19 Patients Finds Hydroxychloroquine (HCQ) Plus Nutritional Protocol Including Nicotinamide Riboside Significantly Improved Recovery Time Vs. HCQ Alone
New Phase 2 Clinical in COVID-19 Patients Finds Hydroxychloroquine (HCQ) Plus Nutritional Protocol Including Nicotinamide Riboside Significantly Improved Recovery Time Vs. HCQ Alone

On the heels of two previously published preclinical studies investigating the effect of viral infection on NAD+ levels, new clinical research in 93 mild-to-moderate COVID-19 infected patients is now available on the open access preprint publication server medRxiv.org.

Read More
Expert AnalysisANAD StaffCOVID-19, Immunity, Clinical Studies